CHIEF COMPLAINT: c/o dimness of vision started in right eye since 2019. Vision is affected more on right eye. Vision on RE is 0/6 and LE is WNL.
PRESENTING ILLNESS: A 41 years old female has been experiencing dimness of vision since 2019, with a greater loss of vision in the right eye compared to the left. Following a visit to an eye hospital, she has been diagnosed with Optic Nerve Atrophy (ONA) attributed to glaucoma. Unfortunately, there is currently no cure or standard care for this condition worldwide. The patient has been informed about the experimental nature of stem cell therapy, specifically using Mesenchymal stem cells (MSCs) derived from umbilical cord tissue and Growth Factor Concentrates (GFCs) from Exosomes. Despite the experimental nature of this treatment, the patient has voluntarily agreed to undergo the experimental stem cell therapy for her optic nerve atrophy. She has been explained well in her own language about the experimental nature of the stem cell therapy.
In this context, it is been made to ensure that the patient fully comprehends the experimental nature of the stem cell therapy, the potential risks and benefits involved, and the absence of established standards of care for her condition.
She has been well-explained about the nature of the therapy in her own language, and she has signed an & “informed consent” & indicating her understanding and willingness to participate. She has voluntarily agreed & signed “informed consent” for the experimental stem cell Rx. She wishes to undergo experimental stem cell therapy for her problem.
